Page 42 - Read Online

Pacheco et al. J Cancer Metastasis Treat 2020;6:49 I http://dx.doi.org/10.20517/2394-4722.2020.85 Page 15 of 15

2005;10:2373-82.
31. Aparisi Gómez MP, Righi A, Errani C, et al. Inflammation and infiltration: can the radiologist draw a line? MRI versus CT to accurately
assess medullary involvement in parosteal osteosarcoma. Int J Biol Markers 2020;35:31-6.
32. Reith JD, Donahue FI, Hornicek FJ. Dedifferentiated parosteal osteosarcoma with rhabdomyosarcomatous differentiation. Skeletal Radiol
1999;28:527-31.
33. Szymanska J, Mandahl N, Mertens F, et al. Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13-15: a combined
cytogenetic and comparative genomic hybridization study. Genes Chromosomes Cancer 1996;16:31-4.
34. Dujardin F, Binh MB, Bouvier C, et al. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-
grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol 2011;24:624-37.
35. Duhamel LA, Ye H, Halai D, et al. Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification
in parosteal and conventional osteosarcoma subtypes. Histopathology 2012;60:357-9.
36. Baumhoer D, Amary F, Flanagan AM. An update of molecular pathology of bone tumors. Lessons learned from investigating samples by
next generation sequencing. Genes Chromosomes Cancer 2019;58:88-99.
37. Bekers EM, Eijkelenboom A, Grünberg K, et al. Myositis ossificans - another condition with USP6 rearrangement, providing evidence of
a relationship with nodular fasciitis and aneurysmal bone cyst. Ann Diagn Pathol. 2018;34:56-9.
38. Meneses MF, Unni KK, Swee RG. Bizarre parostealosteochondromatous proliferation of bone (Nora’s lesion). Am J Surg Pathol
1993;17:691-7.
39. Berber O, Dawson-Bowling S, Jalgaonkar A, et al. Bizarre parostealosteochondromatous proliferation of bone: clinical management of a
series of 22 cases. J Bone Joint Surg Br 2011;93:1118-21.
40. Abramovici L, Steiner GC. Bizarre parostealosteochondromatous proliferation (Nora’s lesion): a retrospective study of 12 cases, 2 arising
in long bones. Hum Pathol 2002;3:1205-10.
41. Lewis VO, Gebhardt MC, Springfield DS. Parosteal osteosarcoma of the posterior aspect of the distal part of the femur. Oncological and
functional results following a new resection technique. J Bone Joint Surg Am 2000;82:1083-8.
42. Han I, Oh JH, Na YG, Moon KC, Kim HS. Clinical outcome of parosteal osteosarcoma. J Surg Oncol 2008;97:146-9.
43. Laitinen M, Parry M, Albergo JI, et al. The prognostic and therapeutic factors which influence the oncological outcome of parosteal
osteosarcoma. Bone Joint J 2015;97:1698-703.
44. Cesari M, Alberghini M, Vanel D, et al. Periosteal osteosarcoma: a single-institution experience. Cancer. 2011;117:1731-5.
45. Chan CM, Lindsay AD, Spiguel ARV, Gibbs CP Jr, Scarborough MT. Periosteal Osteosarcoma: a single-institutional study of factors
related to oncologic outcomes. Sarcoma. 2018;2018:8631237.
46. Grimer RJ, Bielack S, Flege S, et al. Periosteal osteosarcoma:a European review of outcome. Eur J Cancer 2005;41:2806-11.
47. Righi A, Gambarotti M, Benini S, et al. MDM2 and CDK4 expression in periosteal osteosarcoma. Hum Pathol 2015;46:549-53.
48. Ritts GD, Pritchard DJ, Unni KK, Beabout JW, Eckardt JJ. Periosteal osteosarcoma. Clin Orthop Relat Res 1987;219:299-307.
49. Okada K, Unni KK, Swee RG, Sim FH. High grade surface osteosarcoma: a clinicopathologic study of 46 cases. Cancer 1999;85:1044-54.
50. Staals EL, Bacchini P, Bertoni F. High-grade surface osteosarcoma: a review of 25 cases from the Rizzoli Institute. Cancer
2008;112:1592-9.